Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1073/pnas.1522163112 http://scihub22266oqcxt.onion/10.1073/pnas.1522163112 C4697417!4697417!26644586     free     free     free       Proc+Natl+Acad+Sci+U+S+A 2015 ; 112 (51): 15713-8 Nephropedia Template TP {{tp|p=26644586|t=2015. BRD4 is a novel therapeutic target for liver fibrosis |pdf=|usr=}}{{26644586}} gab.com Text BRD4 is a novel therapeutic target for liver fibrosis JO: Proc Natl Acad Sci U S A http://www.kidney.de/pget.php?&tw=1&pmid=26644586 #FOAvip Liver fibrosis and cirrhosis are chronic liver diseases, resulting in life-threatening conditions with no FDA-approved therapy. Here, we identify bromodomain-containing protein 4 (BRD4) as a critical regulator for enhancer-mediated profibrotic gene expression in hepatic stellate cells (HSCs). In support of this notion, we find BRD4-loaded enhancers are associated with multiple profibrotic pathways in HSCs and that pharmacological inhibition of BRD4 blocks HSC activation into myofibroblasts. Furthermore, small molecule inhibitors of BRD4 are not only protective against, but can limit the fibrotic response in CCl4-induced fibrosis in a mouse model. Thus, our studies implicate BRD4 as a global genomic regulator of the fibrotic gene regulatory network and suggest bromodomains as potential therapeutic targets to treat fibrotic complications in patients. Twit Text FOAVip BRD4 is a novel therapeutic target for liver fibrosis ????Proc Natl Acad Sci U S A http://www.kidney.de/pget.php?&tw=1&pmid=26644586 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=26644586 #FOAvip English Wikipedia <ref>{{Cite pmid|26644586}}</ref> BRD4 is a novel therapeutic target for liver fibrosis #MMPMID26644586 Ding N; Hah N; Yu RT; Sherman MH; Benner C; Leblanc M; He M; Liddle C; Downes M; Evans RM Proc Natl Acad Sci U S A 2015[Dec]; 112 (51): 15713-8 PMID26644586show ga Liver fibrosis and cirrhosis are chronic liver diseases, resulting in life-threatening conditions with no FDA-approved therapy. Here, we identify bromodomain-containing protein 4 (BRD4) as a critical regulator for enhancer-mediated profibrotic gene expression in hepatic stellate cells (HSCs). In support of this notion, we find BRD4-loaded enhancers are associated with multiple profibrotic pathways in HSCs and that pharmacological inhibition of BRD4 blocks HSC activation into myofibroblasts. Furthermore, small molecule inhibitors of BRD4 are not only protective against, but can limit the fibrotic response in CCl4-induced fibrosis in a mouse model. Thus, our studies implicate BRD4 as a global genomic regulator of the fibrotic gene regulatory network and suggest bromodomains as potential therapeutic targets to treat fibrotic complications in patients. äBRD4 is a novel therapeutic target for liver fibrosis (epmc).pdf DeepDyve Pubget Overpricing